Dr. Reddy’s launches Sevelamer Carbonate for Oral Suspension in US Market
Dr. Reddy’s Laboratories has launched Sevelamer Carbonate for Oral Suspension, in 0.8 g and 2.4 g packets, a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for Oral Suspension, approved by the U.S. Food and Drug Administration (USFDA).
The Renvela brand and generic had U.S. sales of approximately $101 million MAT for the most recent twelve months ending in October 2018 according to IMS Health. Dr. Reddy’s Sevelamer Carbonate for Oral Suspension is available in 0.8 g and 2.4 g packets in count size of 90.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.